The advent of compact, patient-operated diagnostic devices and AI-based analytics of test data allows physicians to partner with remote monitoring centers and jointly manage patients with retinal disease.
10-year ALOFT study results showed remarkable long-term visual outcomes for patients participating in the Medicare covered, AI-enabled ForeseeHome AMD Monitoring Program, provided by the Notal Vision Monitoring Center. The long-term treatment outcomes of patients whose conversion was detected early using ForeseeHome had an average VA of 20/32 after an average of 2.7 years of treatment.
Our website uses tracking technologies to learn how our visitors interact with our site so that we can improve our services and provide you with valuable content. Disable Tracking.